Your browser doesn't support javascript.
Molnupiravir in COVID-19: A Scoping Review.
Kaore, Shilpa; Atal, Shubham.
  • Kaore S; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India.
  • Atal S; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India.
Curr Drug Res Rev ; 14(3): 203-214, 2022.
Article in English | MEDLINE | ID: covidwho-1875265
ABSTRACT

BACKGROUND:

COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity. It has initiated an era of research on repurposed drugs such as hydroxychloroquine, lopinavir/ritonavir, corticosteroids, remedesivir, ivermectin, alongside selective antivirals to treat or prevent COVID- 19. Molnupiravir is an orally available emerging antiviral drug considered highly promising for COVID-19. METHODS AND

RESULTS:

We have performed a scoping review for the use of molnupiravir against SARS-CoV-2 and COVID-19. It acts by inhibiting RNA-dependent RNA polymerase (RdRp), and exhibits broad-spectrum antiviral activity. Preclinical studies have evaluated the therapeutic efficacy as well as prophylactic activity of molnupiravir against SARS CoV-2 in various animal models that include ferrets, hamsters, mice, immunodeficient mice implanted with human lung tissue and cell cultures, in various doses ranging from 5-300 mg/kg, and results have been encouraging. Initial evidence of safety and efficacy from early phase clinical studies has been encouraging too, and recent results from a large phase 3 global trial have shown significant benefits among symptomatic outpatients. Other late-phase clinical trials are still underway with the aim of establishing molnulpiravir as a therapeutic option for COVID-19, particularly for non-hospitalized patients. CONCLUSION AND RELEVANCE On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Topics: Long Covid Limits: Animals / Humans Language: English Journal: Curr Drug Res Rev Year: 2022 Document Type: Article Affiliation country: 2589977514666220527105158

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Topics: Long Covid Limits: Animals / Humans Language: English Journal: Curr Drug Res Rev Year: 2022 Document Type: Article Affiliation country: 2589977514666220527105158